Guillain-Barré syndrome (GBS) is diagnosed through a combination of clinical examination, spinal fluid analysis, and nerve conduction studies. No single test confirms it on its own. Instead, doctors piece together findings from your symptoms, physical exam, and lab results to build the diagnosis, often while ruling out other conditions that look similar.
What Doctors Look for First
The diagnostic process starts with your symptom history and a neurological exam. GBS typically causes muscle weakness and tingling that comes on suddenly, affects both sides of the body, and starts in the feet and legs before spreading upward to the arms and face. This ascending pattern is one of the hallmarks doctors watch for.
During the physical exam, your doctor will test your deep tendon reflexes by tapping areas like the knee and ankle with a reflex hammer. In GBS, these reflexes are weak or completely absent, a finding called areflexia. The combination of progressive, symmetrical weakness with diminished reflexes is the strongest early clinical signal. If both are present, especially following a recent infection (which triggers GBS in many cases), doctors will move to confirmatory testing.
Spinal Fluid Analysis
A lumbar puncture, sometimes called a spinal tap, is one of the key diagnostic tools. A small sample of cerebrospinal fluid is drawn from the lower back and analyzed in a lab. Doctors are looking for a specific pattern: elevated protein levels alongside a normal or near-normal white blood cell count. This combination is called albuminocytologic dissociation, and it’s considered a hallmark of GBS.
The thresholds are a protein level above 0.45 g/L with fewer than 50 white blood cells per microliter. In practice, about 83% of GBS patients have fewer than 5 white blood cells per microliter in their spinal fluid, and only about 1% exceed 50. If the white cell count is high, it points doctors toward other diagnoses like infection or inflammation of the spinal cord lining.
Timing matters significantly with this test. Spinal fluid protein may not rise until one to two weeks after weakness begins, so a lumbar puncture done in the first few days can come back completely normal. About 10% of GBS patients never develop elevated protein at all. A normal result does not rule out GBS, and doctors may repeat the test later or rely more heavily on other findings.
Nerve Conduction Studies
Nerve conduction studies and electromyography (together called electrodiagnostic testing) measure how well electrical signals travel through your nerves and into your muscles. During the test, small electrodes are placed on your skin, and mild electrical impulses are sent through specific nerves. The speed and strength of the signal help doctors determine whether the nerve’s outer insulation (the myelin sheath) is damaged, whether the nerve fiber itself is injured, or both.
This distinction matters because GBS has several subtypes. The most common form in Western countries involves damage to the myelin sheath, which slows nerve conduction. Another form, called acute motor axonal neuropathy (AMAN), damages the nerve fibers directly and shows a different pattern on testing. Identifying the subtype can influence treatment expectations and recovery timelines.
Like the lumbar puncture, electrodiagnostic studies can be completely normal in the first days of illness. A normal result early on does not rule out GBS. Testing becomes more reliable as the disease progresses, typically after the first week.
Antibody Testing
Blood tests for specific antibodies can support a GBS diagnosis, though they’re more useful for identifying certain variants than for confirming typical cases. These antibodies target gangliosides, which are fat molecules on the surface of nerve cells. When the immune system mistakenly attacks these molecules, it damages the nerves.
For standard GBS, antibody testing has limited sensitivity. One study found that ganglioside antibody testing detected only about 35% of confirmed GBS cases, meaning most patients with the condition will test negative. However, the results are more informative for specific subtypes. In AMAN, combining two types of antibody measurements raised detection to 86%. And for Miller Fisher syndrome (a GBS variant discussed below), anti-GQ1b antibodies are positive in roughly 90% of patients, making this one of the few situations where a single blood test strongly supports the diagnosis.
Because of these limitations, antibody testing is typically used as a supporting tool rather than a standalone diagnostic test. It’s most helpful when the clinical picture is unclear or when a specific variant is suspected.
MRI of the Spine and Brain
MRI isn’t required for every suspected GBS case, but it plays an important role when the diagnosis is uncertain or when doctors need to rule out other conditions like spinal cord compression or stroke. Gadolinium contrast is injected during the scan to highlight areas of inflammation.
In GBS, the nerve roots exiting the spinal cord often become thickened and inflamed. Contrast enhancement of these nerve roots has been found in 95% of typical GBS patients, making it a highly reliable finding. MRI of the brain and cranial nerves can also help detect involvement of the nerves controlling eye movement, facial expression, and swallowing, which some GBS variants affect early.
Diagnosing Miller Fisher Syndrome
Miller Fisher syndrome is a GBS variant with its own distinct presentation. Rather than starting with leg weakness, it causes a triad of three specific signs: eye movement paralysis (difficulty moving the eyes in one or more directions), loss of coordination (ataxia), and absent reflexes (areflexia). This triad appears in about 80% of patients with the condition.
The combination of these three findings, along with a positive anti-GQ1b antibody test, is usually enough to make the diagnosis. MRI of the cranial nerves can provide additional confirmation, particularly in patients whose neurological exam findings are incomplete or ambiguous. Because Miller Fisher syndrome can overlap with other GBS subtypes, some patients develop limb weakness as well, which can complicate the initial assessment.
Why Early Tests Can Be Misleading
One of the most important things to understand about GBS diagnosis is that the condition often outpaces the tests designed to detect it. In the first week of symptoms, spinal fluid protein may still be normal, nerve conduction studies may show no abnormalities, and antibody results may take days to return. Doctors frequently make an initial clinical diagnosis based on the pattern of symptoms and exam findings alone, then confirm it with testing as the disease evolves.
If you or someone you know is experiencing rapidly worsening weakness in both legs, difficulty walking, or tingling that spreads from the feet upward over hours to days, that symptom pattern itself is what prompts urgent evaluation. Doctors don’t wait for test results to begin treatment when the clinical picture is strongly suggestive, because GBS can progress to affect breathing muscles. The formal confirmation often comes after treatment has already started.